AI주식인사이트AI Stock Insight
C

일성아이에스

003120KOSPI의약품 제조업

51.0 / 100

Reference Date: 2026-06-10

Financial Score16.5 / 40
News Sentiment17.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 12.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Ilshin IS is a pharmaceutical company specializing in penicillin antibiotics, collaborating with GSK, and producing key products like Augmentin, which generated 15,404 million won in sales. The company develops and sells medications across endocrine, digestive, and circulatory systems, achieving 64,292 million won in domestic sales during the 66th fiscal year.

Number of Employees

194people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
113.18Industry Average 11.930.0Point

9.5x industry avg (risky)

PBR
0.66Industry Average 0.895.5Point

Lower than industry avg (good)

ROE
0.30Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
0.31Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼9.2% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲8.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -0.4% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 70

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 19,240Won52-week high 28,65052-week low 18,600
1-month return1.0Point

1m -12.55% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15